Loading clinical trials...

Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease | Clinical Trials | Clareo Health

RECRUITINGPHASE4

Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

NCT06917664•China National Center for Cardiovascular Diseases

View on ClinicalTrials.gov

Summary

This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Fully informed and voluntarily signed informed consent;
•2. Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC/EACTS Guidance Standards )

Exclusion Criteria

•1.Symptomatic hypotension and/or a SBP \< 100 mmHg at screening; 2.Estimated GFR \< 30 mL/min/1.73m2; 3.Serum potassium \> 5 mmol/L at screening; 4.History of angioedema or unacceptable side effects while receiving ACE inhibitors or ARBs; 5.Patients receiving mitral valve intervention at the same time, or have participated in other clinical trials, or are unwilling to participate in this study.

Locations (1)

China National Center for Cardiovascular Diseases

Beijing, Beijing Municipality, China

Key Dates

Start Date

June 5, 2025

Primary Completion Date

December 1, 2026

Completion Date

June 1, 2027

Last Updated

August 27, 2025

Enrollment

220

ESTIMATED participants

Conditions

Coronary Artery DiseaseIschemic Mitral RegurgitationAngiotensin Receptor/Neprilysin Inhibitor

Interventions

sacubitril/valsartan

DRUG

Contacts

Lianxin Chen, M.D.

CONTACT

010-88322265 chenlianx1@163.com

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702

Coronary Artery Disease

View study

RECRUITING

"Erectile Function After PCI in MI and Non-MI Patients"

NCT07444697

Erectile DisfunctionCoronary Artery Disease (CAD)+3 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 27, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Inclusion Criteria

Exclusion Criteria

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

"Erectile Function After PCI in MI and Non-MI Patients"

Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease

Product Surveillance Registry

Essential Pro Study ( rEPIC04E-HK )

Factors Affect Outcomes in Cardiovascular Surgery